Development of solid dispersion for poorly water-soluble drugs

Water-Insoluble Drug Formulation, Second Edition

Volumn , Issue , 2008, Pages 499-529

  Vasanthavada, Madhav ^a   Tong, Wei Qin ^a   Serajuddin, Abu T M ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85123270953     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (134)

1. Sekiguchi, K. and N. Obi. 1961. Studies on absorption of eutectic mixture. I. A comparison of the behavior of eutectic mixture of sulfathiazole and that of ordinary sulfathiazole in man. Chem Pharm Bull 9:866-872.
2. Sekiguchi, K., N. Obi, and Y. Ueda. 1964. Studies on absorption of eutectic mixture. II. Absorption of fused conglomerates of chloramphenicol and urea in rabbits. Chem Pharm Bull 12:134-144.
3. Goldberg, A. H., M. Gibaldi, and J. L. Kanig. 1966. Increasing dissolution rates and gastrointestinal absorption of drugs via solid solutions and eutectic mixtures. II. Experimental evaluation of eutectic mixture: Urea-acetaminophen system. J Pharm Sci 55:482-487.
4. Goldberg, A. H., M. Gibaldi, and J. L. Kanig. 1966. Increasing dissolution rates and gastrointestinal absorption of drugs via solid solutions and eutectic mixtures. III. Experimental evaluation of griseofulvin-succinic acid solution. J Pharm Sci 55:487-492.
5. Mayersohn, M. and M. Gibaldi. 1966. New method of solid dispersion for increasing dissolution rates. J Pharm Sci 55:1323-1324.
6. Chiou, W. L. and S. Riegelman. 1969. Preparation and dissolution characteristics of several fast-release solid dispersions of griseofulvin. J Pharm Sci 58:1505-1509.
7. Chiou, W. L. and S. Riegelman. 1971. Pharmaceutical application of solid dispersion systems. J Pharm Sci 60:1281-1302.
8. Serajuddin, A. T. M. 1999. Solid dispersion of poorly water-soluble drugs: Early promises, subsequent problems, and recent breakthroughs. J Pharm Sci 88:1058-1066.
9. Leuner, C. and J. Dressman. 2000. Improving drug solubility for oral delivery using solid dispersions. Eur J Pharm Biopharm 50:47-60.
10. Pudipeddi, M., A. T. M. Serajuddin, and D. Mufson. 2006. Integrated Drug Product Development-From Lead Candidate Selection to Life-Cycle Management. In The Process of New Drug Discovery and Development, eds. C. G. Smith, and J. T. O'Donnell, 2nd ed. 15-51. New York: Informa Healthcare.
11. Serajuddin, A. T. M., S. Ranadive, and E. M. Mahoney. 1991. Relative lipophilicities, solubilities and structure-pharmacological considerations of HMG-CoA reductase inhibitors pravastatin, mevastatin, lovastatin and simvastatin. J Pharm Sci 80:830-834.
12. Serajuddin, A. T. M., P. C. Sheen, and M. A. Augustine. 1986. Preformulation study of a poorly water-soluble drug, a-pentyl-3-(2-quinolinylmethoxy) benzenemethanol: Selection of base for dosage form design. J Pharm Sci 75:492-196.
13. Hancock, B. C. and M. Parks. 2000. What is the true solubility advantage for amorphous pharmaceuticals? Pharm Res 17:397-404.
14. Matsuda, Y. and S. Kawaguchi. 1986. Physicochemical characterization of oxyphenbutazone and solid-state stability of its amorphous form under various temperature and humidity conditions. Chem Pharm Bull 34:1289-1298.
15. Li, S., H. He, L. J. Parthiban, H. Yin, and A. T. M. Serajuddin. 2005. IV-IVC considerations in the development of immediate-release oral dosage form. J Pharm Sci 94:1396-1417.
16. Horter, D. and J. B. Dressman. 1997. Influence of physicochemical properties on dissolution of drugs in the gastrointestinal tract. Adv Drug Delivery Rev 25:3-14.
17. Dannenfelser, R. M., H. He, Y. Joshi, S. Bateman, and A. T. M. Serajuddin. 2004. Development of clinical dosage forms for a poorly water soluble drug I: Application of polyethylene glycol-polysorbate 80 solid dispersion carrier system. J Pharm Sci 93:1165-1175.
18. Flory, P. J. 1953. Principles of Polymer Chemistry. New York: Cornell University Press.
19. Hilderbrand, J. and R. Scott. 1950. The Solubility of Non-Electrolytes. 3rd ed. New York: Reinhold.
20. Coleman, M. M., J. F. Graf, and P. C. Painter. 1991. Specific Interactions and the Miscibility of Polymer Blends. Lancaster: Technomic Publishing Company.
21. Liu, Q. and G. Zografi. 1998. Phase behavior of binary and ternary amorphous mixtures containing indomethacin, citric acid, and PVP. Pharm Res 15:1202-1206.
22. Wang, X., A. Michoel, and G. Van den Mooter. 2005. Solid state characteristics of ternary solid dispersions composed of PVP VA64, Myrj 52 and itraconazole. Int J Pharm 303:54-61.
23. Vishweshwar, R., J. A. Mc. Mahon, J. A. Bis, and M. J. Zaworotko. 2006. Pharmaceutical co-crystals. J Pharm Sci 95:499-514.
24. Karavas, E., G. Ktistis, A. Xenakis, and E. Georgarakis. 2006. Effect of hydrogen bonding interactions on the release mechanism of felodipine from nanodispersions with polyvinylpyrrolidone. Eur J Pharm Biopharm 63:103-114.
25. Yoshioka, M., B. C. Hancock, and G. Zografi. 1995. Inhibition of indomethacin crystallization in poly(vinylpyrrolidone) coprecipitates. J Pharm Sci 84:983-986.
26. Aungst, B. J., N. H. Nguyen, N. J. Rogers, S. M. Rowe, M. A. Hussain, S. J. White, and L. Shum, 1977. Ampiphilic vehicles improve the oral bioavailability of a poorly soluble HIV protease inhibitor at high doses. Int J Pharm 156:79-88.
27. Urbanetz, N. 2006. Stabilization of solid dispersions of nimodipine and polyethylene glycol 2000. Eur J Pharm Sci 28:67-76.
28. Wulff, M., M. Alden, and D. Q. M. Craig. 1996. An investigation into the critical surfactant concentration for solid solubility of hydrophobic drug in different polyethylene glycols. Int J Pharm 142:189-198.
29. Mehta, K. A., M. S. Kislalioglu, W. Phuapradit, W. A. Malik, and N. H. Shah. 2002. Multi-unit controlled release systems of nifedipine and nifedipine: Pluronic® F-68 solid dispersion. Drug Dev Ind Pharm 28:275-285.
30. Karanth, H., V. S. Shenoy, and R. P. Murthy. 2006. Industrially feasible alternative approaches in the manufacture of solid dispersions: A technical report. AAPS Pharm Sci Tech 7:87-96.
31. Breitenbach, J. 2002. Melt extrusion: From process to drug delivery technology. Eur J Pharm Biopharm 54:107-117.
32. Choksi, R. and H. Zia. 2004. Hot-melt extrusion technique: Areview. Iran J Pharm Res 3:107-117.
33. Breitenbach, J., W. Schrof, and J. Neumann. 1999. Confocal Raman spectroscopy: Analytical approach to solid dispersion and mapping of drugs. Pharm Res 16:1109-1113.
34. Verreck, G., K. Six, G. Van den Mooter, L. Baert, J. Peeters, and M. E. Brewster. 2003. Characterization of solid dispersions of itraconazole and hydroxypropylmethylcellulose prepared by melt extrusion-part I. Int J Pharm 251:165-174.
35. Nakamichi, K., H. Yasuura, H. Fukui, M. Oka, and S. Izumi. 2001. Evaluation of a floating dosage form of nicardipine hydrochloride and hydroxypropylmethylcellulose acetate succinate prepared using a twin-screw extruder. Int J Pharm 218:103-112.
36. Li, L., O. Abu Baker, and Z. J. Shao. 2006. Characterization of poly(ethyleneoxide) as a drug carrier in hot-melt extrusion. Drug Dev Ind Pharm 32:991-1002.
37. Forster, A., J. Hempenstall, and T. Rades. 2001. Characterization of glass solutions of poorly water-soluble drugs produced by melt extrusion with hydrophilic amorphous polymers. J Pharm Pharmacol 53:303-315.
38. Hulsmann, S., T. Backensfeld, S. Keitel, and R. Bodmeier. 2000. Melt extrusion-an alternative method for enhancing the dissolution rate of 17-estradiol hemihydrate. Eur J Pharm Biopharm 49:237-242.
39. Chokshi, R. J., H. K. Sandhu, R. M. Iyer, N. H. Shah, A. W. Malick, and H. Zia. 2005. Characterization of physico-mechanical properties of indomethacin and polymers to assess their suitability for hot-melt extrusion process as a means to manufacture solid dispersion/solution. J Pharm Sci 94:2463-2474.
40. Rambali, B., G. Verreck, L. Baert, and D. L. Massart. 2003. Itraconazole formulation studies of the melt extrusion process with mixture design. Drug Dev Ind Pharm 29:641-652.
41. Six, K., T. Daems, J. D. Hoon, A. V. Hecken, M. Depre, M. P. Bouche, P. Prinsen, G. Verreck, J. Peeters, M. E. Brewster, and G. Van den Mooter. 2005. Clinical study of solid dispersions of itraconazole prepared by hot-stage extrusion. Eur J Pharm Sci 24:179-186.
42. Rowley, G. 2004. Filling of liquids and semi-solids into hard two-piece capsules. In Pharmaceutical Capsules, eds. F. Podczeck, and B. E. Jones, 2nd ed. 169-194. Bath: The Batch Press.
43. Robinson, L. 2001. Physical characterization and scale-up manufacture of Gelucire 50/13 based capsule formulations. Bulletin Technique Gattefosse 97:97-111.
44. Ambike, A. A., K. R. Mahadik, and A. Paradkar. 2005. Spray-dried amorphous solid dispersions of simvastatin, a low Tg drug: In vitro and in vivo evaluations. Pharm Res 22:990-998.
45. Sethia, S. and E. Squillante. 2003. Solid dispersions: Revival with greater possibilities and applications in oral drug delivery. Crit Rev Ther Drug Carrier Syst 20:215-247.
46. Elversson, J., A. Millqvist-Fureby, G. Alderborn, and U. Elofsson. 2003. Droplet and particle size relationship and shell thickness of inhalable lactose particles during spray drying. J Pharm Sci 92:900-910.
47. Jung, J. and M. Perrut. 2001. Particle design using supercritical fluids: Literature and patent survey. J Supercrit Fluids 20:179-219.
48. Subramanian, B., R. A. Rajewski, and K. Snavely. 1997. Pharmaceutical processing with supercritical carbon dioxide. J Pharm Sci 86:885-890.
49. Palakodaty, S. and P. York. 1999. Phase behavioral effects on particle formation process using supercritical fluids. Pharm Res 16:976-985.
50. Gong, K., R. Viboonkiat, I. U. Rehman, G. Buckton, and J. A. Darr. 2005. Formation and characterization of porous indomethacin-PVP coprecipitates prepared using solvent-free supercritical fluid processing. J Pharm Sci 2583-2590.
51. Sethia, S. and E. Squillante. 2002. Physicochemical characterization of solid dispersions of carbamazepine formulated by supercritical carbon dioxide and conventional solvent evaporation method. J Pharm Sci 91:1948-1957.
52. Türk, M., B. Helfgen, P. Hils, R. Lietzow, and K. Schaber. 2002. Micronization of pharmaceutical substances by rapid expansion of supercritical solutions (RESS): Experiments and modeling. Particle & Particle Systems Characterization 19:327-335.
53. Vemavarapu, C., M. J. Mollan, and T. E. Needham. 2002. Crystal doping aided by rapid expansion of supercritical solutions. AAPS Pharm Sci Tech 3:1-15.
54. Ting, S. S. T., S. J. Macnaughtn, D. L. Tomasko, and N. R. Foster. 1993. Solubility of naproxen in supercritical carbon dioxide with and without cosolvents. Ind Eng Chem Res 32:1471-1481.
55. 2. J Chem Eng Data 40:216-220.
56. Foster, N., R. Mammucari, F. Dehghani, A. Barrett, K. Bezanehtak, E. Coen, G. Combes, L. Meure, A. Ng, H. L. Regtop, and A. Tandya. 2003. Processing pharmaceutical compounds using dense gas technology. Ind Eng Chem Pres 42:6476-6493.
57. Won, D. H., M. S. Kim, S. Lee, J. S. Park, and S. J. Hwang. 2005. Improved physicochemical characteristics of felodipine solid dispersion particles by supercritical anti-solvent precipitation process. Int J Pharm 301:199-208.
58. Fusaro, F., M., M. Hanchen, M. Mazzotti, G. Muhrer, and B. Subramaniam. 2005. Dense gas antisolvent precipitation: A comparative investigation of the GAS and PCA techniques. Ind Eng Chem Res 44:1502-1509.
59. Muhrer, G., U. Meier, F. Fusaro, S. Albano, and M. Mazzotti. 2006. Use of compressed gas precipitation to enhance the dissolution behavior of a poorly water-soluble drug: Generation of drug microparticles and drug-polymer solid dispersions. Int J Pham 308:69-83.
60. Jarmer, D. J., C. S. Lengsfeld, K. S. Anseth, and T. W. Randolph. 2005. Supercritical fluid crystallization of griseofulvin: Crystal habit modification with a selective growth inhibitor. J Pharm Sci 94:2688-2702.
61. Edwards, A. D., B. Y. Shekunov, A. Kordikowski, R. T. Forbes, and P. York. 2001. Crystallization of pure anhydrous polymorphs of carbamezapine by solution enhanced dispersion with supercritical fluids (SEDS). J Pharm Sci 90:1115-1124.
62. Vasanthavada, M. and A. T. M. Serajuddin. Lipid-based self-emulsifying solid dispersions. In Lipid-Based Formulations for Oral Drug Delivery: Enhancing the Bioavailability of Poorly Water-Soluble Drugs, ed. D. J. Hauss, 149-183. New York: Informa Healthcare.
63. Serajuddin, A. T. M., P. C. Sheen, D. Mufson. D. F. Bernstein, and M. A. Augustine. 1988. Effect of vehicle amphiphilicity on the dissolution and bioavailability of a poorly water-soluble drugs from solid dispersions. J Pharm Sci 77:414-417.
64. Al-Razzak, L. A., L. Dias, D. Kaul, and S. Ghosh. 1997. Lipid based systems for oral delivery: Physiological mechanistic and product development perspectives. Paper presented at the AAPS Annual Meeting, Boston, November 2-6, 1997.
65. Barker, S. A., S. P. Yap, K. H. Yuen, C. P. McCoy, J. R. Murphy, and D. Q. M. Craig. 2003. An investigation into the structure and bioavailability of A-tocopherol dispersions in Gelucire 44/14. J Controlled Release 91:477-488.
66. Vippagunta, S. R., K. A. Maul, S. Tallavajhala, and D. J. W. Grant. 2002. Solid-state characterization of nifedipine solid dispersions. Int J Pharm 236:111-123.
67. He, Y., J. L. H. Johnson, and S. H. Yalkowsky. 2005. Oral formulation of a novel antiviral agent, PG301029, in a mixture of Gelucire 44/14 and DMA (2:1, wt/wt). AAPS PharmSci Tech 6:1-5.
68. Soliman, M. S. and M. A. Khan. 2005. Preparation and in vitro characterization of a semi solid dispersion of flurbiprofen with Gelucire 44/14 and Labrasol. Pharmazie 60:288-293.
69. Nilufer, Y., K. Aysegul, O. Yalcin, S. Ayhan, A. O. Sibel, and B. Tamer. 2003. Enhanced bioavailability of piroxicam using Gelucire 44/14 and Labrasol: In vitro and in vivo evaluation. Eur J Pharm Biopharm 235:247-265.
70. Serajuddin, A. T. M., P. C. Sheen PC, and M. A. Augustine. 1990. Improved dissolution of a poorly water-soluble drug from solid dispersions in poly(ethylene glycol)-polysorbate 80 mixtures. J Pharm Sci 79:463-464.
71. Morris, K. R., G. T. Knipp, and A. T. M. Serajuddin. 1992. Structural properties of poly(ethylene glycol)-polysorbate 80 mixture, a solid dispersion vehicle. J Pharm Sci 81:1185-1188.
72. Joshi, H. N., R. W. Tejwani, M. Davidovich, V. P. Sahasrabudhe, M. Jemal, M. S. Bathala, S. A. Varia, and A. T. M. Serajuddin. 2004. Bioavailability enhancement of a poorly water-soluble drug by solid dispersion in polyethylene glycol-polysorbate 80 mixture. Int J Pharm 269:251-258.
73. Veiga, M. D., C. Escobar, and M. J. Bernard. 1993. Dissolution behavior of drugs from binary and ternary systems. Int J Pharm 93:215-220.
74. Sheen, P. C., V. K. Khetarpal, C. M. Cariola, and C. E. Rowlings. Formulation studies of a poorly water-soluble drug in solid dispersions to improve bioavailability. Int J Pharm 18:221-227.
75. Yu, L., A. Bridgers, J. Polli, A. Vickers, S. Long, A. Roy, R. Winnike, and M. Coffin. 1999. Vitamin-E TPGS increases absorption flux of an HIV protease inhibitor by enhancing its solubility and permeability. Pharm Res 16:1812-1817.
76. Khoo, S. M., C. J. H. Porter, and W. N. Charman. 2000. The formulation of halofantrine as either non-solubilising PEG6000 or solubilising lipid based solid dispersion: Physical stability and absolute bioavailability assessment. Int J Pharm 205:65-78.
77. Varma, M. V. and R. Panchagnula. 2005. Enhanced oral paclitaxel absorption with Vitamin E-TPGS: Effect on solubility and permeability in vitro, in situ and in vivo. Eur J Pharm Sci 25:445-453.
78. Wu, S. H., 1998. Vitamin E TPGS as a vehicle for drug delivery system. Paper presented at AAPS short course Formulation with Lipids, Parsippany, NJ, June 3, 1998.
79. Boudreaux, J. P., D. H. Hayes, S. Mizrahi, P. Maggiore, J. Blazek, and D. Dick. 1993. Use of water-soluble liquid Vitamin E to enhance cyclosporine absorption in children after liver transplant. Transplant Proc 25:1875-1881.
80. Sokol, R. J., N. Butler-Simon, C. Connor, J. E. Heui, F. R. Sinatra, F. J. Suchy, M. B. Heyman, J. Perrault, R. J. Rothbaum, and J. Levy. 1993. Multicenter trial of D-a-Tocopheryl Polyethylene Glycol 1000 succinate for treatment of Vitamin E deficiency in children with chronic choleostasis, Gastroenterology 104:1727-1735.
81. Chang, T., L. Z. Benet, and M. F. Hebert. 1996. The effect of water-soluble vitamin E on cyclosporine pharmacokinetics in healthy volunteers. Clin Pharmacol Ther 59:297-303.
82. Shin, S. C. and C. W. Cho. 1997. Physicochemical characterization of piroxicam-poloxamer solid dispersion. Pharm Dev Technol 2:403-407.
83. Ho, H.O., C. N. Chen, and M.T. Sheu. 2000. Influence of pluronic F-68 on dissolution and biavailability characteristics of multiple-layer pellets of nifedipine for controlled release delivery. J Control Release 68:433-440.
84. Passerini, N., B. Albertini, and M. L. Gonzalez-Rodriguez. 2002. Preparation and characterization of ibuprofen-poloxamer 188 granules obtained by melt granulation. Eur J Pharm Sci 15:71-78.
85. Chen, Y., G. G. Z. Zhang, J. Neilly, K. Marsh, D. Mawhinney, and Y. D. Sanzgiri. 2004. Enhancing the bioavailability of ABT-963 using solid dispersion containing Pluronic F-68. Int J Pharm 286:69-80.
86. Yin, S. X., M. Franchini, J. L. Chen, A. Hsieh, S. Jen, T. Lee, M. Hussain, and R. Smith. 2005. Bioavailability enhancement of a COX-2 inhibitor, BMS-347070, from nanocrystalline dispersion prepared by spray-drying. J Pharm Sci 94:1598-1607.
87. Patil, P., J. Joshi, and P. Paradkar. 2004. Effect of formulation variables on preparation and evaluation of gelled self-emulsifying drug delivery systems (SEDDS) of ketoprofen. AAPS Pharm Sci Tech 5:1-8.
88. Itai, S., M. Nemoto, S. Kouchiwa, H. Murayama, and T. Nagai. 1985. Influence of wetting factors on the dissolution behavior of flufenamic acid. Chem Pharm Bull 33:5464-5473.
89. Bates, T. R. 1969. Dissolution characteristics of reserpine-polyvinylpyrrolidone co-precipitates. J Pharm Pharmacol 21:710-712.
90. Simonelli, A. P., S. C. Mehta, and W. I. Higuchi. 1969. Dissolution rates of high energy polyvinylpyrrolidone (PVP)-sulfathiazole coprecipitates. J Pharm Sci 58:538-549.
91. Tantishaiyakul, V., N. Kaewnopparat, and S. Ingkatawornwong. 1999. Properties of solid dispersions of piroxicam in polyvinylpyrrolidone. Int. J. Pharm 181:143-151.
92. Simonelli, A. P., S. C. Mehta, and W. I. Higuchi. 1970. Inhibition of sulfathiazole crystal growth by polyvinylpyrrolidone. J Pharm Sci 59:633-638.
93. Doherty, C. and P. York. 1989. Accelerated stability of an x-ray amorphous furesemide polyvinyl pyrrolidone solid dispersions. Drug Dev Ind Pharm 15:1969-1987.
94. Perng, C. Y., A. S. Kearney, K. Patel, N. R. Palepu, and G. Zuber. 1998. Investigation of formulation approaches to improve the dissolution of SB-210661, a poorly water soluble 5-lipoxygenase inhibitor. Int J Pharm 176:31-38.
95. Kohri, N., Y. Yamayoshi, H. Xin, K. Iseki, N. Sato, S. Todo, and K. Miyazaki. 1999. Improving the oral bioavailability of albendazole in rabbits by the solid dispersion technique. J Pharm Pharmacol 51:159-164.
96. Sugimoto, I., K. Sasaki, A. Kuchiki, T. Ishihara, and H. Nakagawa. 1982. Stability and bioavailability of nifedipine in fine granules. Chem Pharm Bull 30:4479-4488.
97. Usui, F., K. Maeda, A. Kusai, K. Nishimura, and K. Yamamoto. 1991. Inhibitory effects of water-soluble polymers on precipitation of RS-8359. Int J Pharm 154:59-66.
98. Shanker, R. M. 2005. Current concepts in the science of solid dispersion, 2nd Annual Simonelli Conference in Pharmaceutical Sciences, June 9, Long Island University.
99. Tanno, F., Y. Nishiyama, H. Kokubo, and S. Obara. 2004. Evaluation of hypromellose acetate succinate (HPMC AS) as a carrier in solid dispersions. Drug Dev Ind Pharm 30:9-17.
100. Veiga, M. D., M. J. Bernard, and C. Escobar. 1993. Thermal behavior of drugs from binary and ternary systems. Int J Pharm 89:119-124.
101. Bikiaris, D., G. Z. Papageorgiou, A. Stergiou, E. Pavlidou, E. Karavas, F. Kanaze, and M. Georgarakis. 2005. Physicochemical studies on solid dispersions of poorly water-soluble drugs. Evaluation of capabilities and limitations of thermal analysis techniques. Thermochnica Acta 439:58-67.
102. Galop, M. 2005. Study of pharmaceutical solid dispersions by microthermal analysis. Pharm Res 22:293-302.
103. Shmeis, R. A., Z. Wang, and S. L. Krill. 2004. A mechanistic investigation of an amorphous pharmaceutical and its solid dispersion, Part I: A comparative analysis by thermally stimulated depolarization current and differential scanning calorimetry. Pharm Res 21:2025-2030.
104. Vasanthavada, M., Z. Wang, Y. Joshi, and M. S. Kislalioglu. 2002. Comparison of the utility of thermally stimulated current and modulated differential scanning calorimeter to study sub-glass transition molecular motions of poly(vinylpyrrolidone). Paper presented at AAPS Annual Meeting, Toronto, October 8, 2002.
105. Taylor, L. S. and G. Zografi. 1997. Spectroscopic characterization of interactions between PVP and Indomethacin in amorphous molecular dispersions. Pharm Res 14:1691-1698.
106. Geppi, M., S. Guccione, G. Mollica, R. Pignatello, and C. A. Veracini. 2005. Molecular properties of ibuprofen and its solid dispersions with Eudragit RL 100 studies by solid-state nuclear magnetic resonance. Pharm Res 22:1544-1555.
107. Schachter, D. M., J. Xiong, and G. C. Tirol. 2004. Solid-state NMR perspective of drug-polymer solid solutions: A model system based on poly(ethyleneoxide). Int J Pharm 281:89-101.
108. Craig, D. Q. M. 2002. The mechanism of drug release from solid dispersions in water-soluble polymers. Int J Pharm 231:131-144.
109. Serajuddin, A. T. M., A. B. Thakur, R. N. Ghoshal, M. G. Fakes, S. A. Ranadive, K. R. Morris, and S.A. Varia. 1999. Selection of dosage form composition through drug-excipient compatibility testing. J Pharm Sci 88:696-704.
110. Chen, G. L. and W. H. Hao. 1998. Factors affecting zero-order release kinetics of porous gelatin capsules. Drug Dev Ind Pharm 24:557-562.
111. Johnson, D. M. and W. F. Taylor. 1984. Degradation of feprostalene in polyethylene glycol 400 solution. J Pharm Sci 73:1414-1417.
112. Bindra, D. S., T. D. Williams, and V. J. Stella. 1994. Degradation of O-6-Benzylguanine in aqueous polyethylene glycol 400 (PEG 400) solutions: Concerns with formaldehyde in PEG 400. Pharm Res 11:1060-1064.
113. Bergh, M., K. Magnusson, J. Lars, G. Nilson, and A. T. Karlberg. 1998. Formation of formaldehyde and peroxides by air oxidation of high purity polyoxyethylene surfactants. Contact Dermatitis 39:14-20.
114. Frontini, R. and J. B. Mielck. 1995. Formationofformaldehydeinpolyethyleneglycolandinpoloxamer under stress conditions. Int J Pharm 114:121-123.
115. Bergh, M., L. P. Shao, G. Hagelthorn, E. Gafvert, J. L. G. Nilsson, and A. T. Karlberg. 1998. Contact allergens from surfactants. Atmospheric oxidation of polyoxyethylene alcohols, formation of ethoxylated aldehydes, and their allergenic activity. J Pharm Sci 87:276-282.
116. Ford, J. L. 1986. The current status of solid dispersions. Pharm Acta Helv 61:69-88.
117. Chiou, W. L. 1977. Pharmaceutical applications of solid dispersions: X-ray diffraction and aqueous solubility studies on griseofulvin-poly(ethylene glycol) 6000 systems. J Pharm Sci 66:989-991.
118. Suzuki, H. and H. Sunada. 1998. Some factors influencing the dissolution of solid dispersions with nicotinamide and hydroxypropylmethylcellulose as combined carriers. Chem Pharm Bull 46:1015-1020.
119. Guillaume, F. and A. M. Guyot-Hermann. 1992. Elaboration and physical study of an oxodipine solid dispersion in order to formulate tablets. Drug Dev Ind Pharm 18:811-829.
120. Liu, C., J. Wu, B. Shi, Y. Zhang, T. Gao, and Y. Pei. 2006. Enhancing the bioavailability of cyclosporine A using solid dispersion containing polyoxyethylene (40) stearate. Drug Dev Ind Pharm 32:115-123.
121. Hancock, B. C. and S. L. Shamblin. 2001. Molecular mobility of amorphous pharmaceuticals determined using differential scanning calorimetry. Thermochim Acta 380:95-107.
122. Shamblin, S. L., L. S. Taylor, and G. Zografi. 1998. Mixing behavior of colyophilized binary systems. J Pharm Sci 87:694-701.
123. Craig, D. Q. M., P. G. Royall, V. L. Kett, and M. L. Hopton. 1999. The relevance of the amorphous state to pharmaceutical dosage forms: Glassy drugs and freeze dried systems. Int J Pharm 179:179-207.
124. Khougaz, K. and S. D. Clas. 2000. Crystallization inhibition in solid dispersions of MK-0591 and poly(vinylpyrrolidone) polymer. J Pharm Sci 89:1325-1334.
125. Chang, I., F. Fujara, B. Geil, G. Heuberger, T. Mangel, and H. J. Sillescu. 1994. Translational and rotational molecular motion in supercooled liquids studies by NMR and forced Rayleigh scattering. J Non Crys Solids 172:248-255.
126. Marsac, P. J., H. Konno, and L. S. Taylor. 2006. A comparison of the physical stability of amorphous felodipine and nifedipine systems. Pharm Res 23:2306-2316.
127. Zhou, D. G., G. Z. Zhang, D. Law, D. J. W. Grant, and E. A. Schmitt. 2002. Physical stability of amorphous pharmaceuticals: Importance of configurational thermodynamic quantities and molecular mobility. J Pharm Sci 91:1863-1872.
128. Johari, G. P., S. Kim, and R. M. Shanker. 2005. Dielectric studies of molecular motions in amorphous solid and ultraviscous acetaminophen. J Pharm Sci 94:2207-2223.
129. Gunawan, L., G. P. Johari, and R. M. Shanker. 2006. Sructural relaxation of acetaminophen glass. Pharm Res 23:967-979.
130. Bhugra, C., R. Shmeis, S. L. Krill, and M. J. Pikal. 2006. Predictions of onset of crystallization from experimental relaxation times I-correlation of molecular mobility from temperatures above the glass transition to temperatures below the glass transition. Pharm Res 23:2277-2290.
131. Zhou, D., D. J. W. Grant, G. G. Z. Zhang, D. Law, and E. A. Schmitt. 2007. A calorimetric investigation of thermodynamic and molecular mobility contributions to the physical stability of two pharmaceutical glasses. J Pharm Sci 96:71-83.
132. Vasanthavada, M., W. Tong, Y. Joshi, and M. S. Kislalioglu. 2004. Phase behavior of amorphous molecular dispersions I: Determination of the degree and mechanism of solid solubility. Pharm Res 21:1598-1606.
133. Vasanthavada, M., W. Tong, Y. Joshi, and M. S. Kislalioglu. 2005. Phase behavior of amorphous molecular dispersions II: Role of hydrogen bonding in solid solubility and phase separation kinetics. Pharm Res 22:440-448.
134. Weuts, I., D. Kempen, A. Decorte, G. Verreck, J. Peeters, M. Brewster, and G. Van den Mooter. 2005. Physical stability of the amorphous state of loperamide and two fragment molecules in solid dispersions with the polymers PVP-K30 and PVP-VA64. Eur J Pharm Sci 25:313-320.